Aducanumab: evidence from clinical trial data and controversies
Open accessAbstract
Alzheimer's disease (AD) is the most common cause for dementia worldwide. Until recently, all approved treatments for AD were symptomatic and not disease modifying. On 7 June 2021, the US FDA approved aducanumab, a human IgG1 anti-Aβ monoclonal antibody selective for Aβ aggregates, as the first disease-modifying treatment for AD. Aducanumab is approved in the United States for the treatment of mild cognitive impairment or mild-dementia stage of AD. In this Editorial, we review the trial data for aducanumab in the treatment of AD and the controversies that its approval has generated.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The US FDA approved aducanumab as the first disease-modifying treatment for AD in 2021.
“Thus, the US FDA has approved aducanumab as the first disease-modifying treatment for AD in 2021.529”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [529]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 20 · Cited by 190
Research works printed but not linked: 13
- [3]Miziak B Błaszczyk B Czuczwar SJ Some candidate drugs for pharmacotherapy of Alzheimer’s disease Pharmaceuticals 2021 14 5 458 10.3390/ph14050458 34068096 PMC8152728 · DOI
- [5]Mufson EJ Counts SE Perez SE Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications Expert Rev Neurother 2008 8 11 1703 1718 10.1586/14737175.8.11.1703 18986241 PMC2631573 · DOI
- [6]Cummings JL Tong G Ballard C Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options J Alzheimers Dis 2019 67 3 779 794 10.3233/JAD-180766 30689575 PMC6398562 · DOI · Paper page
- [15]Morant AV Jagalski V Vestergaard HT Characteristics of single pivotal trials supporting regulatory approvals of novel non-orphan, non-oncology drugs in the European Union and United States from 2012–2016 Clin Transl Sci 2019 12 4 361 370 10.1111/cts.12617 30681284 PMC6662549 · DOI
- [17]Liu KY Schneider LS Howard R The need to show minimum clinically important differences in Alzheimer’s disease trials Lancet Psychiatry 2021 S2215-0366(21)00197-8 10.1016/S2215-0366(21)00197-8 34087114 · DOI · Paper page
- [19]Lin GA Whittington MD Synnott PG Aducanumab for Alzheimer’s disease: effectiveness and value; draft evidence report Institute for Clinical and Economic Review 5 5 2021 https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Draft_Evidence_Report_050521.pdf Accessed August 23, 2021
- [20]Cummings J Salloway S Aducanumab: appropriate use recommendations Alzheimers Dement 2021 10.1002/alz.12444 PMC8792094 34314093 · DOI · Paper page
- [21]Mullard A FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm Nat Rev Drug Discov 2021 20 7 496 10.1038/d41573-021-00099-3 34112945 · DOI
- [22]Fleck LM Alzheimer’s and aducanumab: unjust profits and false hopes Hastings Cent Rep 2021 51 4 9 11 10.1002/hast.1264 34156732 · DOI
- [25]Flurry of Investigations Beset Aducanumab Alzaforum https://www.alzforum.org/news/conference-coverage/flurry-investigations-beset-aducanumab Accessed August 28, 2021
- [27]Decourt B Boumelhem F Pope ED 3rd Critical Appraisal of Amyloid Lowering Agents in AD Curr Neurol Neurosci Rep 2021 21 8 39 10.1007/s11910-021-01125-y 34110536 PMC8192384 · DOI
- [28]Marasco RA Current and evolving treatment strategies for the Alzheimer disease continuum Am J Manag Care 2020 26 Suppl 8 S167 S176 10.37765/ajmc.2020.88481 32840330 · DOI
- [29]Liu JL Hlavka JP Hillestad R Mattke S Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer’s treatment RAND Corporation https://www.rand.org/pubs/research_reports/RR2272.html Accessed June 30, 2021 PMC6557037 31205802
- Authors
- Tampi, R. R., Forester, B. P., & Agronin, M.
- Affiliations
- Yale University (US)
- Harvard University (US)
- Corresponding author
- Tampi, Rajesh R
- Venue
- Drugs in Context
- Publisher
- BioExcel
- Published
- 2021-10-04
- Volume
- 10
- Pages
- 1-9
- ISSN
- 1740-4398 (ISSN-L)
- PMC
- PMC8491638
- OpenAlex
- W3204222713
- Cited by
- 190
- References
- 20
- Citations by year
- 2026: 13 · 2025: 33 · 2024: 43 · 2023: 56 · 2022: 44 · 2021: 1
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Drugs in Context (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid-beta aggregates, anti-amyloid monoclonal antibodies, disease-modifying therapy, FDA approval, clinical trial data, mild cognitive impairment, mild dementia, amyloid PET
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
